{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:28:30Z","timestamp":1792546110903,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.annonc.2021.10.213","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T12:37:57Z","timestamp":1635770277000},"page":"80-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":97,"title":["89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer"],"prefix":"10.1016","volume":"33","author":[{"given":"I.C.","family":"Kok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"Hooiveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.P.","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Giesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.L.","family":"van der Veen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.N.","family":"Lub-de Hooge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.H.","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.J.N.","family":"Hiltermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"van der Wekken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.B.M.","family":"Hijmering-Kappelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Timens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.G.","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.A.P.","family":"Hospers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.J.M.","family":"Groen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Uyterlinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"van der Hiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.B.","family":"Haanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.J.A.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Jalving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.G.E.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2021.10.213_bib1","doi-asserted-by":"crossref","first-page":"e1920833","DOI":"10.1001\/jamanetworkopen.2019.20833","article-title":"Assessment of clinical activity of PD-1 checkpoint inhibitor combination therapies reported in clinical trials","volume":"3","author":"Schmidt","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.annonc.2021.10.213_bib2","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.10.213_bib3","doi-asserted-by":"crossref","first-page":"k4226","DOI":"10.1136\/bmj.k4226","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"Br Med J"},{"key":"10.1016\/j.annonc.2021.10.213_bib4","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.5858\/arpa.2015-0542-OA","article-title":"Development of a companion diagnostic for pembrolizumab in non-small cell lung cancer using immunohistochemistry for programmed death ligand-1","volume":"140","author":"Dolled-Filhart","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.annonc.2021.10.213_bib5","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2217\/imt-2016-0150","article-title":"PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data","volume":"9","author":"Aguiar","year":"2017","journal-title":"Immunotherapy"},{"key":"10.1016\/j.annonc.2021.10.213_bib6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Pembrolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2021.10.213_bib7","first-page":"30445","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"20","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.10.213_bib8","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jamaoncol.2019.2311","article-title":"Multiomics prediction of response rates to therapies to inhibit programmed cell death 1 and programmed cell death 1 ligand 1","volume":"5","author":"Lee","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2021.10.213_bib9","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.10.213_bib10","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2021.10.213_bib11","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.7150\/thno.26370","article-title":"Comparative biodistribution analysis across four different 89Zr-monoclonal antibody tracers\u2014the first step towards an imaging warehouse","volume":"8","author":"Bensch","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.annonc.2021.10.213_bib12","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","article-title":"89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","volume":"24","author":"Bensch","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2021.10.213_bib13","doi-asserted-by":"crossref","first-page":"e000938","DOI":"10.1136\/jitc-2020-000938","article-title":"89Zr-pembrolizumab biodistribution is influenced by PD-1 mediated uptake in lymphoid organs","volume":"8","author":"Van der Veen","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2021.10.213_bib14","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2967\/jnumed.113.130112","article-title":"Multicenter harmonization of 89Zr PET\/CT performance","volume":"55","author":"Makris","year":"2014","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.annonc.2021.10.213_bib15","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1148\/radiol.14132807","article-title":"Repeatability of metabolically active tumor volume measurements with FDG PET\/CT in advanced gastrointestinal malignancies: a multicenter study","volume":"273","author":"Frings","year":"2014","journal-title":"Radiology"},{"key":"10.1016\/j.annonc.2021.10.213_bib16","doi-asserted-by":"crossref","first-page":"780458","DOI":"10.1155\/2013\/780458","article-title":"A\u00a0partial volume effect correction tailored for 89F-FDG-PET oncological studies","volume":"2013","author":"Gallivanone","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.annonc.2021.10.213_bib17","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1053\/j.seminoncol.2017.06.002","article-title":"A\u00a0molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab","volume":"44","author":"Fessas","year":"2017","journal-title":"Semin Oncol"},{"key":"10.1016\/j.annonc.2021.10.213_bib18","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1038\/s41467-018-07131-y","article-title":"Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small cell lung cancer","volume":"9","author":"Niemeijer","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2021.10.213_bib19","article-title":"First-in-human study of 89Zr-pembrolizumab PET\/CT in patients with advanced stage non-small-cell lung cancer","author":"Niemeijer","year":"2021","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.annonc.2021.10.213_bib20","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s11307-020-01558-w","article-title":"PET\/CT Imaging of 89Zr-N-sucDf-pembrolizumab in healthy cynomolgus monkeys","volume":"23","author":"Li","year":"2021","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.annonc.2021.10.213_bib21","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3389\/fimmu.2020.00487","article-title":"The role of PD-1 in acute and chronic infection","volume":"11","author":"Jubel","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.annonc.2021.10.213_bib22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.annonc.2021.10.213_bib23","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/pcmr.12340","article-title":"PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1\/PD-L1 clinical trials","volume":"28","author":"Madore","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.annonc.2021.10.213_bib24","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1158\/1078-0432.CCR-15-1714","article-title":"PD-L1 negative status is associated with lower mutation burden, differential expression of immune-related genes, and worse survival in stage III melanoma","volume":"22","author":"Madore","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2021.10.213_bib25","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.21873\/anticanres.12662","article-title":"Heterogeneity of PD-L1 expression and relationship with biology of NSCLC","volume":"38","author":"Bassanelli","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.annonc.2021.10.213_bib26","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.lungcan.2019.06.005","article-title":"Heterogeneity of PD-L1 expression in non-small cell lung cancer: implications for specimen sampling in predicting treatment response","volume":"134","author":"Haragan","year":"2019","journal-title":"Lung Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421047499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421047499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:07:33Z","timestamp":1760335653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753421047499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0923753421047499"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2021.10.213","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2021.10.213","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}